| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular and Cellular Biology, December 2007, p. 8421-8430, Vol. 27, No. 24
0270-7306/07/$08.00+0 doi:10.1128/MCB.00504-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Laboratory of Molecular Biology, Medical Research Council, Cambridge, United Kingdom,1 Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia2
Received 22 March 2007/ Returned for modification 10 September 2007/ Accepted 3 October 2007
The Fanconi anemia (FA) nuclear core complex and the E2 ubiquitin-conjugating enzyme UBE2T are required for the S phase and DNA damage-restricted monoubiquitination of FANCD2. This constitutes a key step in the FA tumor suppressor pathway, and much attention has been focused on the regulation at this point. Here, we address the importance of the assembly of the FA core complex and the subcellular localization of UBE2T in the regulation of FANCD2 monoubiquitination. We establish three points. First, the stable assembly of the FA core complex can be dissociated of its ability to function as an E3 ubiquitin ligase. Second, the actual E3 ligase activity is not determined by the assembly of the FA core complex but rather by its DNA damage-induced localization to chromatin. Finally, UBE2T and FANCD2 access this subcellular fraction independently of the FA core complex. FANCD2 monoubiquitination is therefore not regulated by multiprotein complex assembly but by the formation of an active E2/E3 holoenzyme on chromatin.
Published ahead of print on 15 October 2007.
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|